Can a Cholesterol-Lowering shot reverse brain artery blockages?

NCT ID NCT06902740

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a PCSK9 inhibitor (Recaticimab) to standard statin therapy can reverse plaque buildup in brain arteries of people with asymptomatic intracranial atherosclerosis. About 300 participants will receive either the drug combo or statins alone for 24 weeks. The main goal is to see if plaque burden decreases on MRI scans, which could lower future stroke risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Recaticimab (a PCSK9 inhibitor) combined with statin (rosuvastatin or atorvastatin)
What this could lead to
If successful, this could show that adding a PCSK9 inhibitor to statins reverses artery plaque in the brain, potentially reducing stroke risk.
What could go wrong
This is a Phase 4 trial with 300 participants, but it is open-label (not blinded for patients) and uses imaging endpoints rather than clinical outcomes like stroke reduction. Results may not translate to fewer strokes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASYMPTOMATIC INTRACRANIAL ATHEROSCLEROTIC STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Baotou Central Hospital

    NOT_YET_RECRUITING

    Baotou, Inner Mongolia, 014000, China

  • Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine

    NOT_YET_RECRUITING

    Cangzhou, Hebei, China

  • Chinese PLA General Hospital

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, 100853, China

  • Chongqing General Hospital

    NOT_YET_RECRUITING

    Chongqing, China

  • First Affiliated Hospital of Harbin Medical University

    NOT_YET_RECRUITING

    Harbin, Heilongjiang, China

  • Hebei Provincial People's Hospital

    RECRUITING

    Shijiazhuang, Hebei, 050051, China

  • Huashan Hospital, Fudan University

    NOT_YET_RECRUITING

    Shanghai, China

  • Jining First People's Hospital

    NOT_YET_RECRUITING

    Jining, Shandong, 272000, China

  • Liaocheng People's Hospital

    NOT_YET_RECRUITING

    Liaocheng, Shandong, 252000, China

  • Nanjing First Hospital

    NOT_YET_RECRUITING

    Nanjing, Jiangsu, 210000, China

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

  • Peking University Third Hospital Qinhuangdao Hospital

    NOT_YET_RECRUITING

    Qinhuangdao, Hebei, China

  • Taihe Hospital

    NOT_YET_RECRUITING

    Shiyan, Hubei, 442000, China

  • Tangshan Worker's Hospital

    NOT_YET_RECRUITING

    Tangshan, Hebei, 063000, China

  • The Affiliated Hospital of Qingdao University

    NOT_YET_RECRUITING

    Qingdao, Shandong, China

  • The Third Affiliated Hospital of Sun Yat-sen University, Yuedong Hospital

    NOT_YET_RECRUITING

    Meizhou, Guangdong, China

  • The first affiliated hospital of zhengzhou university

    NOT_YET_RECRUITING

    Zhengzhou, Henan, China

  • Weifang People's Hospital

    NOT_YET_RECRUITING

    Weifang, Shandong, 261000, China

  • Zhongnan Hospital of Wuhan University

    NOT_YET_RECRUITING

    Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.